AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.23
+1.21%0
Insider buys (3m)
10
Insider sells (3m)
-$1.7M
Net value (3m)
+46.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 679 | $20 |
| Sep 1, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 679 | $8.04 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | Sale | 37,945 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | M-Exempt | 2,876 | $9.88 |
| Aug 19, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 1,000 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | Sale | 31,031 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | M-Exempt | 37,945 | $9.88 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | Sale | 3,749 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | M-Exempt | 31,031 | $9.88 |
| Aug 19, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 1,000 | $13 |
| Aug 12, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 679 | $20 |
| Aug 12, 2026 | Riley Jennifer · officer: Chief Strategy Officer | Sale | 2,655 | $20 |
| Aug 12, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 679 | $8.04 |
| Jul 29, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 1,000 | $20 |
| Jul 29, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 1,000 | $13 |
| Jul 2, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 4,654 | $20 |
| Jul 2, 2026 | Lind Kevin Robert · director | A-Award | 1,105 | $18 |
| Jul 2, 2026 | Philip Ron M · director | A-Award | 69 | $18 |
| Jul 2, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 1,779 | $8.04 |
| Jul 2, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 2,875 | $13 |
| Jul 2, 2026 | Jain Rita · director | A-Award | 1,080 | $18 |
| Jun 25, 2026 | Philip Ron M · director | A-Award | 40,200 | $18 |
| Jun 25, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 1,450 | $8.04 |
| Jun 25, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 1,450 | $18 |
| Jun 12, 2026 | Doyle Mittie · officer: Chief Medical Officer | F-InKind | 1,084 | $13 |
| Jun 12, 2026 | Riley Jennifer · officer: Chief Strategy Officer | F-InKind | 588 | $13 |
| Jun 12, 2026 | VARKI PAUL · officer: Chief Legal Officer | F-InKind | 1,081 | $13 |
| Jun 12, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | F-InKind | 138 | $13 |
| Jun 4, 2026 | KAPLAN GILLA · director | A-Award | 20,100 | $14 |
| Jun 4, 2026 | Truex Samantha · director | A-Award | 20,100 | $14 |
Institutional positioning
13F filings over the trailing two quarters
New 35Increased 34Reduced 20Sold out 100
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 2,879,481 | May 15, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | New Position | 2,162,684 | May 15, 2026 |
| CALIGAN PARTNERS LP | Increased | 1,635,023 | May 15, 2026 |
| BVF INC/IL | Increased | 1,632,845 | May 15, 2026 |
| AVORO CAPITAL ADVISORS LLC | New Position | 1,410,000 | May 15, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 1,340,840 | May 14, 2026 |
| LOGOS GLOBAL MANAGEMENT LP | New Position | 1,300,000 | May 15, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Unchanged | 1,235,000 | May 15, 2026 |
| UBS GROUP AG | Increased | 1,141,980 | May 5, 2026 |
| CAPTION MANAGEMENT, LLC | Increased | 1,086,700 | May 15, 2026 |
| POINT72 ASSET MANAGEMENT, L.P. | Increased | 916,142 | May 15, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | New Position | 916,000 | May 15, 2026 |
| RTW INVESTMENTS, LP | New Position | 856,962 | May 15, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Increased | 854,000 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 835,484 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 1, 2026